First-line antiretroviral therapy in Africa - How evidence-based are our recommendations?

AIDS Reviews

Volumn 7, Issue 3, 2005, Pages 148-154

  Colebunders, Robert ^a,b,c   Kamya, Moses R ^a   Laurence, John ^a   Kambugu, Andrew ^a   Byakwaga, Helen ^a   Mwebaze, Patricia Songa ^a   Muganga, Alex Muganzi ^a   Katwere, Michael ^a   Katabira, Elly ^a  

^a MAKERERE UNIVERSITY   (Uganda)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Antiretroviral therapy; Countries with limited resources; First line therapy; HIV; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AFRICA; ANEMIA; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INFECTION RISK; LACTIC ACIDOSIS; LIPOATROPHY; LIVER TOXICITY; METABOLIC ACIDOSIS; MONOTHERAPY; MORTALITY; NEURITIS; POPULATION DISTRIBUTION; PRACTICE GUIDELINE; PREGNANCY; PRIMARY HEALTH CARE; REVIEW; SKIN TOXICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUBERCULOSIS; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

AFRICA; ANTI-HIV AGENTS; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HUMANS; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 27944510618     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. WHO. Scaling up antiretroviral therapy in resource limited settings: treatment guidelines for a public health approach. 2003 revision. Geneva: WHO; 2003. Available at URL: http://www.who.int/3by5/publications/documents/arv_guidelines/en Accessed 4 January 2004.
2. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach-2003 Revision. Available at URL: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf
3. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004; 363:1253-63.
4. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study. HIV Clin Trials 2002; 3:296-303.
5. Phillips A, Ledergerber B, Horban A, et al. EuroSIDA Study Group. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004;18:1795-804.
6. Klein M, Willemot P, Murphy T, Lalonde R. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004;18:1895-904.
7. Asamoah-Odei E, Garcia Calleja J, Boerma J. HIV prevalence and trends in sub-Saharan Africa: no decline and large subregional differences. Lancet 2004;364:35-40.
8. Jeannin A, Pinoges L, Calmy A, et al. Clinical and virological outcomes of patients on HAART in a large-scale simplified treatment program in a rural district of Malawi. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris 2003 (abstract 625).
9. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-95.
10. Hudspeth J, Venter W, van Rie A, Wing J. Feldman C. Access to and early outcomes of a public South African adult antiretroviral clinic. 12th Conference on Retroviruses and Opportunistic Infections. Boston 2005 [abstract 625].
11. Stringer J, Zulu I, Chi B, et al. Rapid deployment of ART services is feasible and effective in resource-limited settings in sub-Saharan Africa. 12th Conference on Retroviruses and Opportunistic Infections. Boston 2005 [abstract 638].
12. Ndwapi N, Bussman H, Gaolathe T, et al. Response to the Botswana national antiretroviral therapy program-preliminary analysis of the first 306 treatment naïve adults receiving HAART via the national ARV program. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris 2003 [abstract 1216].
13. Kabugo C, Bahendeka S, Mwebaze R, et al. Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. J Acquir Immune Defic Syndr 2005;38:578-83.
14. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004;364:29-34.
15. Jack C, Lalloo U, Karim QA, et al. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004;36:929-34.
16. Kebba A, Atwine D, Mwebaze R, Kityo C, Nakityo R, Peter M. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses 2002;18:1181-7.
17. Mosam A, Cassol E, Page T, et al. Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa. AIDS 2005;19:441-3.
18. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med 2004;5:105-9.
19. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005;38:174-9.
20. Pujari S, Patel A, Naik E, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr 2004;37:1566-9.
21. Pujari S, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005;39:199-202.
22. Kulwichit W. First-line and second-line antiretroviral therapy. Lancet 2004;364:329-30.
23. Patel S, Johnson S, Belknap S, Chan J, Sha B, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 2004;35:120-5.
24. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003;4:62-6.
25. Negredo E, Ribalta J, Ferre R, et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004;18:819-21.
26. Wilson DP, Blower SM. Designing equitable antiretroviral allocation strategies in resource-constrained countries. PLoS Med 2005;2: e50.
27. Milinkovic A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2004;2:367-73.
28. Mackie N, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004;5:180-4.
29. Kumarasamy N. Generic antiretroviral drugs-will they be the answer to HIV in the developing world? Lancet 2004;364:3-4.
30. Narang V, Lulla A, Malhotra G, Purandare S. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects. J Clin Pharmacol 2005;45:265-74.
31. Winston A, Pozniak A, Smith N, et al. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals? AIDS 2004;18:572-4.
32. Nakwagala F, Kagimu M. Hepatitis B virus and HIV infections among patients in Mulago hospital. East Afr Med J 2002;79:68-72.
33. Baylor M, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004;35:538-9.
34. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004;18:767-74.
35. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005;191:825-9.
36. Phanuphak N, Apornpong T, Intarasuk S, Teeratakulpisarn S, Phanuphak P. Toxicities from nevirapine in HIV-infected males and females, including pregnant females with various CD4 cell counts. 12th Conference on Retroviruses and Opportunistic Infections. Boston 2005 [abstract 21].
37. Arribas J. Efavirenz: enhancing the gold standard. Int J of STD & AIDS 2004;14:6-14.
38. Ferrer E, Santamarina E, Domingo P, et al. Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/μl or less. AIDS 2004;18:1727-9.
39. Hitti J, Frenkel L, Stek A, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36:772-6.
40. Van Der Sande M, Schim Van Der Loeff M, Bennett R, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004;18:1933-41.
41. Ribera E, Pou L, Lopez R, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001;28:450-3.
42. Oliva J, Moreno S, Sanz J, et al. Coadministration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003;17:637-8.
43. Taylor G, Low-Beer N. Antiretroviral therapy in pregnancy: a focus on safety. Drug Saf 2001;24:683-702.
44. Mitchell H, Stephens E. Contraception choice for HIV positive women. Sex Transm Infect 2004;80:167-73.
45. Ribaudo H, Clifford D, Gulick R, et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: Results from ACTG A5095/A5097s. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, California, USA February 8-11, 2004, [abstract 132].
46. Haas D, Ribaudo H, Kim R, et al. Common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG Study NWCS214. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, California, USA; February 8-11, 2004 [abstract 133].
47. De Maat M, Nellen J, Huitema A, et al. Race is not associated with nevirapine pharmacokinetics. Ther Drug Monit 2004;26:456-8.
48. Muro E, Droste J, ter Hofstede H, Bosch M, Dolmans W, Burger D. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose NVP: implications for intervention studies. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, California, USA; February 8-11, 2004 [abstract 891].
49. Taylor S, Allen S, Fidler S, et al. Stop Study: After discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, California, USA; February 8-11, 2004 [abstract 131].
50. Nkengasong J, Adje-Toure C, Weidle PJ. HIV antiretroviral drug resistance in Africa. AIDS Rev 2004;6:4-12.
51. DeJesus E, McCarty D, Farthing C, et al. EPV20001 International Study Team. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004;39:411-8.
52. Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1 infected adults in Senegal. AIDS 2003;17:1017-22.
53. Jackson J, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-68.
54. Eshleman S, Guay L, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nevirapine prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004;20:595-99.
55. Eshleman S, Guay L, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004;35:126-30.
56. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-40.
57. Gazzard B, Pozniak A, Rosenbaum W, et al. An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17:F49-54.
58. Colebunders R, Kolsteren P, Ryder R. Editorial: Giving antiretrovirals in the peripartum period to prevent mother-to-child HIV transmission in low-income countries: only a short-term stopgap measure. Trop Med Int Health 2003;8:375-7.
59. Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003;17:2045-52.
60. Wong M, Robertson K, Nakasujja N, et al. HIV-associated neurological complications among HIV-seropositive individuals in Uganda. Neurology 2004;62 (suppl 5):A444.
61. Ndiaye I, Ndiaye M, Mauferon J, Diagne M, Diop A. Etiological aspects of polyneuritis in Senegal. Dakar Med 1989;34:68-71.
62. Dicko A, Klion A, Thera M, et al. The etiology of severe anemia in a village and a peri-urban area in Mali. Blood 2004;104:1198-200.
63. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B HIV type 1. AIDS Res Hum Retroviruses 2004;20:355-64.